Steven T Leach1, Andrew S Day2, Rachel Messenger3, Thomas D Walters4, Victor M Navas-López5, Malgorzata Sladek6, Annecarin Brückner7, Baruch Yerushalmi8, Shehzad Saeed9, Anthony Otley10, David Mack11,12, Matan Gavish13, Dan Turner14, Anne M Griffiths4, Daniel A Lemberg3. 1. School of Women's and Children's Health, University of New South Wales, Sydney, Australia. 2. Department of Paediatrics, University of Otago (Christchurch), Christchurch, New Zealand. 3. Department of Gastroenterology, Sydney Children's Hospital Randwick, Sydney, Australia. 4. Division of Gastroenterology, Hospital for Sick Children, Toronto, Ontario, Canada. 5. Pediatric Gastroenterology and Nutrition Unit. Hospital Materno. IBIMA. Málaga, Spain. 6. Jagiellonian University Medical College, Krakow, Poland. 7. Dr. von Hauner Children's Hospital, Ludwig Maximilians University Munich, Germany. 8. Pediatric Gastroenterology Unit, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheba, Israel. 9. Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. 10. Division of Gastroenterology and Nutrition, Department of Pediatrics, Dalhousie University, IWK Health Centre, Halifax, Canada. 11. Children's Hospital of Eastern Ontario (CHEO) Inflammatory Bowel Disease Centre and CHEO Research Institute, Ottawa, Ontario, Canada. 12. Department of Pediatrics, University of Ottawa, Ottawa, Canada. 13. School of Computer Science and Engineering. 14. Juliet Keidan Institute of Paediatric Gastroenterology, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel.
Abstract
BACKGROUND: Noninvasive and accurate methods to monitor inflammatory bowel disease are required. As a planned ancillary study of the prospective ImageKids cohort, we aimed to assess the performance of fecal calprotectin (FC) with comparison to 3 fecal inflammatory markers; S100A12 (FA12), tumor pyruvate kinase isoenzyme type M2 (FM2PK) and fecal osteoprotegerin (FOPG) as indicators of a number of disease characteristics. METHODS: The ImageKids study was a multicenter study designed to develop 2 magnetic resonance enterography-based measures for children with Crohn disease (6-18 years old). All patients underwent magnetic resonance enterography, a complete ileocolonoscopic evaluation and provided a fecal sample. Fecal samples were assay for FC, FA12, FM2PK, and FOPG by ELISA. RESULTS: One-hundred fifty-six children provided 190 fecal samples. Median (interquartile range) for fecal makers were FC, 602 (181-1185) μg/g; FA12, 21 (3-109) μg/g; FM2PK, 16 (2-20) U/mL; and FOPG, 125 (125-312) μg/g. All markers correlated with simple endoscopic severity index for Crohn disease and with other constructs of disease activity, but FC had the highest overall correlations. FA12, however, predicted mucosal healing with significantly higher specificity (87% vs 70%, P = 0.004) and equivalent sensitivity (91% vs 90%) compared to FC. CONCLUSION: This study has confirmed that FC is useful, and overall best, marker to monitor mucosal inflammation in inflammatory bowel disease. FA12, however, appears to be a more suitable maker for prediction of mucosal healing in children.
BACKGROUND: Noninvasive and accurate methods to monitor inflammatory bowel disease are required. As a planned ancillary study of the prospective ImageKids cohort, we aimed to assess the performance of fecal calprotectin (FC) with comparison to 3 fecal inflammatory markers; S100A12 (FA12), tumor pyruvate kinase isoenzyme type M2 (FM2PK) and fecal osteoprotegerin (FOPG) as indicators of a number of disease characteristics. METHODS: The ImageKids study was a multicenter study designed to develop 2 magnetic resonance enterography-based measures for children with Crohn disease (6-18 years old). All patients underwent magnetic resonance enterography, a complete ileocolonoscopic evaluation and provided a fecal sample. Fecal samples were assay for FC, FA12, FM2PK, and FOPG by ELISA. RESULTS: One-hundred fifty-six children provided 190 fecal samples. Median (interquartile range) for fecal makers were FC, 602 (181-1185) μg/g; FA12, 21 (3-109) μg/g; FM2PK, 16 (2-20) U/mL; and FOPG, 125 (125-312) μg/g. All markers correlated with simple endoscopic severity index for Crohn disease and with other constructs of disease activity, but FC had the highest overall correlations. FA12, however, predicted mucosal healing with significantly higher specificity (87% vs 70%, P = 0.004) and equivalent sensitivity (91% vs 90%) compared to FC. CONCLUSION: This study has confirmed that FC is useful, and overall best, marker to monitor mucosal inflammation in inflammatory bowel disease. FA12, however, appears to be a more suitable maker for prediction of mucosal healing in children.
Authors: Ruben J Colman; Yi-Ting Tsai; Kimberly Jackson; Brendan M Boyle; Joshua D Noe; Jeffrey S Hyams; Geert R A M D'Haens; Johan van Limbergen; Michael J Rosen; Lee A Denson; Phillip Minar Journal: Inflamm Bowel Dis Date: 2021-06-15 Impact factor: 7.290
Authors: María Roca; Ana Rodriguez Varela; Eva Carvajal; Ester Donat; Francisco Cano; Ana Armisen; Maria Jose Vaya; Helena Ekoff; David Hervas; Niclas Rydell; Carmen Ribes-Koninckx Journal: Sci Rep Date: 2020-11-25 Impact factor: 4.379
Authors: Martina Orfei; Marco Gasparetto; Kai O Hensel; Florian Zellweger; Robert B Heuschkel; Matthias Zilbauer Journal: PLoS One Date: 2021-02-11 Impact factor: 3.240